Severe cutaneous adverse reactions linked to medications in children and adolescents: a pharmacovigilance study based on the FDA Adverse Event Reporting System database
International Journal of Clinical Pharmacy · 2025
DOI: 10.1007/s11096-025-02063-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Clinical Pharmacy, 2025. Verfasst von Yaping Xiao und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Chongqing University Three Gorges Hospital, 165 Xincheng Road, Wanzhou District, Chongqing, 404000, China. Hauptthemen laut MEDLINE: Adverse Drug Reaction Reporting Systems, Pharmacovigilance, United States Food and Drug Administration, Databases, Factual. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: the 2024 Science-Health Collaborative Research Program of the Wanzhou District, Chongqing.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
INTRODUCTION: Severe cutaneous adverse reactions (SCARs) are rare but potentially life-threatening. Children and adolescents are especially vulnerable due to developmental pharmacology, immature immune systems, and limited premarketing safety data. However, large-scale evidence of drug-specific SCAR patterns in pediatric populations remains limited. AIM: To investigate the epidemiology, clinical features, drug associations, and safety signals of SCARs in children and adolescents using the FDA Adverse Event Reporting System (FAERS). METHOD: Reports of SCARs in patients aged ≤ 18 years were retrieved from FAERS from Q1 2004 to Q2 2024 and identified using narrow-scope Standardised MedDRA Queries (SMQs). Data cleaning followed the FDA-recommended procedures. Disproportionality analysis was performed using four methods: Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN; yielding Information Component, IC), Multi-item Gamma Poisson Shrinker (MGPS), and empirical Bayes geometric mean (EBGM). Drug-label reviews were used to compare the signal detection results with existing safety warnings. RESULTS: A total of 7183 pediatric SCAR reports were included. The number of reports has increased over time, with adolescents (13-17 years) and school-aged children (7-12 years) accounting for 68% of cases. The most frequently reported Preferred Terms were drug reaction with eosinophilia and systemic symptoms (DRESS; 32.5%), Stevens-Johnson syndrome (SJS; 27.9%), and toxic epidermal necrolysis (TEN; 19.0%). Hospitalization occurred in 64.5% of cases, and 6.3% were fatal. Among the 2005 cases with available onset time, 82.7% developed within 30 days of drug exposure. Thirty-eight drugs showed positive signals, including lamotrigine, phenytoin, sulfamethoxazole, and phenobarbital. Four drugs, ranitidine, anakinra, clonazepam, and rifampin, showed signals without corresponding warnings in the FDA pediatric labeling. CONCLUSION: SCARs in children and adolescents show distinct patterns, high hospitalization and mortality, and strong links with antiepileptics and anti-infectives. Strengthening pediatric pharmacovigilance, implementing risk-alert systems, and promoting genotype-guided prescribing may help prevent these severe reactions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacy, Chongqing University Three Gorges Hospital, 165 Xincheng Road, Wanzhou District, Chongqing, 404000, China.
- School of Medicine, Chongqing University, Chongqing, China.
- Department of Pharmacy, Chongqing University Three Gorges Hospital, 165 Xincheng Road, Wanzhou District, Chongqing, 404000, China. 18696850703@163.com.
- School of Medicine, Chongqing University, Chongqing, China. 18696850703@163.com.
Förderung
- the 2024 Science-Health Collaborative Research Program of the Wanzhou District, Chongqing
Zitieren
APA
Xiao, Y., Guo, H., Deng, L., Huang, J., & Sun, Q. (2025). Severe cutaneous adverse reactions linked to medications in children and adolescents: a pharmacovigilance study based on the FDA Adverse Event Reporting System database. International Journal of Clinical Pharmacy. https://doi.org/10.1007/s11096-025-02063-2
Vancouver
Xiao Y, Guo H, Deng L, Huang J, Sun Q. Severe cutaneous adverse reactions linked to medications in children and adolescents: a pharmacovigilance study based on the FDA Adverse Event Reporting System database. International Journal of Clinical Pharmacy. 2025. doi:10.1007/s11096-025-02063-2
BibTeX
@article{Xiao2025,
author = {Xiao, Yaping and Guo, Hu and Deng, Lijuan and Huang, Jieyao and Sun, Qiuyan},
title = {Severe cutaneous adverse reactions linked to medications in children and adolescents: a pharmacovigilance study based on the FDA Adverse Event Reporting System database},
journal = {International Journal of Clinical Pharmacy},
year = {2025},
doi = {10.1007/s11096-025-02063-2}
}
EUVIMED